These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36083788)

  • 1. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
    Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
    J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
    Ma T; Chen X; Wang M
    Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
    Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
    Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
    Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
    Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
    Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
    Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment.
    Wang S; Zhu Y; Du S; Zheng Y
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
    Rosenblum D; Gutkin A; Kedmi R; Ramishetti S; Veiga N; Jacobi AM; Schubert MS; Friedmann-Morvinski D; Cohen ZR; Behlke MA; Lieberman J; Peer D
    Sci Adv; 2020 Nov; 6(47):. PubMed ID: 33208369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing.
    Chang J; Chen X; Glass Z; Gao F; Mao L; Wang M; Xu Q
    Acc Chem Res; 2019 Mar; 52(3):665-675. PubMed ID: 30586281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Special Focus Issue Part II: Recruitment of solid lipid nanoparticles for the delivery of CRISPR/Cas9: primary evaluation of anticancer gene editing.
    Akbaba H; Erel-Akbaba G; Senturk S
    Nanomedicine (Lond); 2021 May; 16(12):963-978. PubMed ID: 33970666
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of nanoparticles in CRISPR/Cas9-based gene therapy].
    Ma Y; Deng L; Li S
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2087-2104. PubMed ID: 35786464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.